ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets brand-name and generic prescription pharmaceuticals in the United States and Canada. The company is headquartered in Baudette, Minnesota.
| Revenue (TTM) | $883.37M |
| Gross Profit (TTM) | $542.06M |
| EBITDA | $174.75M |
| Operating Margin | 12.00% |
| Return on Equity | 16.20% |
| Return on Assets | 3.82% |
| Revenue/Share (TTM) | $44.05 |
| Book Value | $25.80 |
| Price-to-Book | 3.38 |
| Price-to-Sales (TTM) | 2.12 |
| EV/Revenue | 2.434 |
| EV/EBITDA | 10.37 |
| Quarterly Earnings Growth (YoY) | -16.90% |
| Quarterly Revenue Growth (YoY) | 29.60% |
| Shares Outstanding | $22.75M |
| Float | $19.34M |
| % Insiders | 7.37% |
| % Institutions | 99.96% |
Volatility is currently contracting